Stay updated with breaking news from Tycel Philips. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.
The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after 2 or more lines of systemic therapies.
Approval for the T-cell–engaging bispecific antibody came today from the FDA.